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Introduction
It is now recognized that metabolism plays a key role in the activation and specialized functions of  immune 
cells. Cells fuel ATP production through 2 major metabolic pathways: glycolysis (the metabolic breakdown 
of  glucose) and oxidative phosphorylation (the synthesis of  ATP in the presence of  oxygen). For T cells, 
macrophages, and DCs, inflammatory activation is associated with metabolic reprogramming from a rela-
tively metabolically quiescent state to a highly glycolytic state (1–4). These metabolic changes are thought 
to assist the generation of  biosynthetic precursors for effector functions. For example, high glycolytic flux 
can produce nucleotide precursors for cell division in T cells (5), citrate for production of  ROS in macro-
phages (6), and lipid precursors for ER membrane synthesis in DCs (7). Glycolytic enzymes have also been 
shown to directly regulate cytokine production and gene expression in T cells (8, 9). Thus, in many immune 
cell types, metabolic regulation equips activated cells to carry out specialized functions.
NK cells are innate cytotoxic lymphocytes that are first responders against virally infected cells and 
tumor cells. They respond within hours of  stimulation by releasing cytokines, such as IFN-γ, and killing 
target cells. Stimulation with cytokines for longer periods, including inflammatory cytokines such as IL-12 
and IL-15, significantly enhances NK cell functions. Recent studies have demonstrated that certain NK cell 
responses require metabolic cues. Naive NK cells rely on glucose-fueled oxidative phosphorylation, while 
expansion with IL-15 elevates metabolic rates with a preference toward glycolysis, similar to changes seen 
during the activation of  CD8+ T cells (10, 11). Several studies show that NK cell production of  the cyto-
kine IFN-γ is regulated by metabolism (10, 12–14). We previously demonstrated that, in freshly isolated 
murine NK cells, IFN-γ production after short-term receptor activation is highly dependent on glycolytic 
NK cell activation has been shown to be metabolically regulated in vitro; however, the role of 
metabolism during in vivo NK cell responses to infection is unknown. We examined the role of 
glycolysis in NK cell function during murine cytomegalovirus (MCMV) infection and the ability of 
IL-15 to prime NK cells during CMV infection. The glucose metabolism inhibitor 2-deoxy-ᴅ-glucose 
(2DG) impaired both mouse and human NK cell cytotoxicity following priming in vitro. Similarly, 
MCMV-infected mice treated with 2DG had impaired clearance of NK-specific targets in vivo, which 
was associated with higher viral burden and susceptibility to infection on the C57BL/6 background. 
IL-15 priming is known to alter NK cell metabolism and metabolic requirements for activation. 
Treatment with the IL-15 superagonist ALT-803 rescued mice from otherwise lethal infection in an 
NK-dependent manner. Consistent with this, treatment of a patient with ALT-803 for recurrent CMV 
reactivation after hematopoietic cell transplant was associated with clearance of viremia. These 
studies demonstrate that NK cell–mediated control of viral infection requires glucose metabolism 
and that IL-15 treatment in vivo can reduce this requirement and may be effective as an antiviral 
therapy.
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and oxidative metabolism, while IFN-γ production stimulated by cytokine activation (IL-12 + IL-18) is 
independent of  both metabolic pathways. We found that receptor activation depends less on these metabol-
ic pathways after priming with high-dose IL-15 (10). Others have found that after expansion in IL-15 and 
stimulation with IL-2 + IL-12, highly activated lymphokine-activated killer (LAK) cells require glycolysis 
for maximal production of  IFN-γ and the cytotoxic granule protein granzyme B (Gzmb) (12). Studies in 
human NK cells show a similar pattern — IFN-γ and Gzmb production downstream of  certain stimuli is 
sensitive to metabolic inhibition (13). Together, these studies demonstrate that NK cells have specific met-
abolic requirements for IFN-γ and Gzmb production. Few studies have directly examined the metabolic 
regulation of  other NK cell functions, such as target killing and proliferation. Here, we investigate the role 
of  glycolysis in NK cell cytotoxicity in vitro and in vivo in response to viral infection.
NK cells are particularly important for antiviral responses against cytomegalovirus. In response to 
human cytomegalovirus (HCMV), NK cells bearing the activating NKG2C receptor rapidly expand and 
persist (15, 16). These cells, termed CMV-adapted NK cells, display enhanced responses, particularly when 
triggered by antibodies through their Fc receptor (17–20). While the adaptive T cell response to HCMV is 
required for long-term immunity, evidence from B cell– and T cell–deficient patients demonstrates that the 
expansion of  NKG2C+ NK cells alone can control HCMV infection (21).
Acute infection with murine cytomegalovirus (MCMV) in C57BL/6 mice is well described to be con-
trolled by NK cells (22–26). During the first 2 days of  infection, NK cells are activated by circulating cyto-
kines and respond by producing a burst of  immunomodulatory cytokines, most notably IFN-γ (27). After 
day 2, expression of  the virally encoded ligand m157 on the surface of  infected cells leads to the expansion 
of  Ly49H+ NK cells, which specifically recognize and kill m157-expressing cells (28–31). Thus, this murine 
system can be used to examine NK cell activation and proliferation, and the killing of  infected cells in vivo; 
it is also a model for human infection.
In the current study, we found that NK cell proliferation and cytotoxicity following IL-15 priming in 
vitro were impaired when NK cells were cultured with the glucose metabolism inhibitor 2-deoxy-ᴅ-glucose 
(2DG), which blocks the first 2 enzymes of  glycolysis. Glycolytic inhibition decreased expression of  cyto-
toxic proteins and altered the adhesion of  NK cells to target conjugates. In vivo, treatment of  MCMV-re-
sistant C57BL/6 mice with 2DG caused significant susceptibility to infection and was associated with 
impaired NK-mediated clearance of  m157+ targets. Similar susceptibility to infection was also observed 
when animals were treated with rapamycin, a drug that inhibits the mTOR pathway. Priming with the 
IL-15 superagonist ALT-803 rescued 2DG- or rapamycin-treated animals from lethal infection. 2DG also 
decreased human NK cell cytotoxicity in vitro; here, we describe a hematopoietic cell transplant (HCT) 
patient with recurrent CMV reactivation treated with ALT-803. Similar to findings in our murine model, 
ALT-803 treatment in this patient was associated with clearance of  viremia, suggesting therapeutic poten-
tial for IL-15 agonists in CMV.
Results
Inhibiting glucose metabolism with 2DG decreases NK cell proliferation and cytotoxicity in vitro. Murine NK cells 
require activation, such as priming with IL-15, to upregulate cytotoxic effector molecules, such as Gzmb, 
and effectively kill target cells (32). To investigate the requirement for glucose metabolism in NK cytotox-
icity, NK cells were purified from WT C57BL/6 mice and plated in 100 ng/ml IL-15 with or without 1 
mM 2DG for 72 hours. This dose of  2DG maintained NK cell viability, with minimal differences between 
treated and untreated cells (Supplemental Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/jci.insight.95128DS1). Extracellular flux assays confirmed that 2DG treat-
ment significantly decreased NK cell glycolysis, as measured by the extracellular acidification rate (ECAR) 
(Figure 1A). We previously demonstrated that naive murine NK cells primarily use glucose-based oxida-
tive phosphorylation (10). Consistent with this, 2DG treatment also decreased the oxygen consumption 
rate (OCR) (Figure 1A). 2DG significantly inhibited IL-15–induced proliferation (Figure 1B), leading to a 
reduction in the number of  cells recovered at the end of  the incubation (Supplemental Figure 1B).
The ability of  NK cells to kill target cells after priming with IL-15 with or without 2DG was measured 
at various effector-to-target ratios (E:T ratios) in complete media. Ba/F3-m157 cells are murine pro-B cells 
ectopically expressing the MCMV-encoded protein m157 that is recognized by Ly49H+ NK cells, and kill-
ing of  Ba/F3-m157 is mediated solely by Ly49H-expressing NK cells (29, 33, 34). Killing of  Ba/F3-m157 
targets was significantly impaired when activated in the presence of  2DG (Figure 1C). NK cell killing of  
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MHC class I–deficient RMA-S tumor cells (35, 36) was also significantly impaired by 2DG. Interestingly, 
killing of  YAC-1 tumor cells, which are primarily recognized by NKG2D (37–39), was not impaired by 
2DG (Supplemental Figure 1C). These results suggest that glycolytic inhibition caused target-specific defi-
cits in NK cell killing, possibly based on different mechanisms of  target cell recognition and NK activation.
Decreased killing by 2DG-treated NK cells is associated with low Gzmb and variable actin accumulation during 
target conjugation. We investigated several mechanisms by which 2DG might decrease NK cell cytotoxicity. 
First, IL-15 increases levels of  cytotoxic granule proteins in NK cells (32). Treatment with 2DG reduced 
expression of  Gzmb (Figure 2A), suggesting one potential mechanism for decreased NK cell cytotoxicity. 
Next, we investigated the dynamics of  NK cell recognition and killing of  target cells. Target cell killing is 
a tightly orchestrated event composed of  multiple steps including recognition of  the target cell, adhesion, 
and formation of  an immunological synapse (IS), anchoring to the target with filamentous F-actin, conver-
gence of  granules to the microtubule organizing center (MTOC), polarization and trafficking of  the MTOC 
toward the IS, degranulation, and finally detachment (40). By flow cytometry, 2DG did not significantly 
decrease NK cell recognition of  potential targets, as demonstrated by normal conjugate formation between 
2DG-treated NK cells and Ba/F3-m157 targets (Figure 2B). Confocal microscopy of  cocultured NK cells 
and Ba/F3-m157 targets also demonstrated conjugate formation by 2DG-treated NK cells (Figure 2C). 
In some conjugates in both treatment groups, Ly49H was detected at the synapse (Figure 2D). However, 
actin accumulation at the IS was highly variable among 2DG-treated NK cells, indicating that 2DG may 
impair proper adhesion to the target (Figure 2, C and E). Compared with control-treated NK cells, most 
2DG-treated NK cells had negative actin accumulation, indicating abnormal anchoring to the target and 
impaired commitment to killing (Figure 2E). However, 2DG did not affect polarization of  the MTOC, as 
measured by the distance of  the MTOC to the IS (Figure 2F), suggesting that once NK cells committed 
to killing, MTOC polarization was not impaired. Thus, these data demonstrate that inhibition of  glucose 
metabolism interfered with NK cell priming, leading to decreased levels of  Gzmb protein production and 
altered actin accumulation at the IS.
Figure 1. Glucose metabolism blockade during activation decreases NK cell proliferation and cytotoxicity. Purified NK cells were cultured for 72 hours in 
100 ng/ml IL-15 without (black) or with 1 mM 2-deoxy-ᴅ-glucose (2DG, green). (A) Representative extracellular flux assay showing glycolytic rate as esti-
mated by extracellular acidification rate (ECAR); glycolytic stress test shows baseline ECAR in glucose-free media and after addition of glucose, maximal 
ECAR after addition of oligomycin, and nonglycolytic acidification after 2DG. Summary data shows ECAR, oxygen consumption rate (OCR), and the OCR/
ECAR ratio normalized to control (n = 4/group in 3 separate experiments, ratio paired t test performed on raw data). (B) Representative histogram shows 
CFSE dilution of proliferating NK cells. Summary graph shows the percentage of NK cells proliferated (n = 5 experiments, paired t test). (C) NK cells activat-
ed in IL-15 ± 2DG were assessed for their ability to kill Ba/F3-m157 target cells at different effector/target ratios (ratios represent Ly49H+ NK cells/targets), 
n = 8/group, 4 experiments, 2-way ANOVA. Data show mean ± SEM. *P < 0.05, ***P < 0.001.
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2DG-treated, MCMV-infected mice have impaired target clearance day 2 after infection. To examine the effects 
of  glycolytic inhibition on NK cell function in vivo, we treated MCMV-infected mice with 2DG. Female 
WT mice were infected i.p. with 1 × 105 PFU of  MCMV (~40% LD50) (41) and injected daily with either 
19 mg (1 g/kg) of  2DG or vehicle (PBS). To determine whether 2DG administration altered NK cell 
cytotoxicity, in vivo target clearance was assessed. Syngeneic WT splenocytes (nontargets) and transgenic 
splenocytes (targets) expressing the MCMV-encoded activating ligand m157, which is only recognized by 
Ly49H+ NK cells, were differentially labeled and adoptively transferred into infected mice 2 days after 
infection (42). Clearance of  targets in 2DG-treated MCMV-infected mice was significantly lower than in 
PBS-treated MCMV-infected mice and was similar to baseline clearance in mock-infected mice (Figure 
3A). This finding suggests that 2DG treatment impaired NK cell activation with MCMV infection and 
subsequent killing of  target cells.
Figure 2. In vitro treatment with 2DG decreases NK cell production of granzyme B and alters actin accumulation at the immunological synapse. Purified 
NK cells were cultured for 72 hours in 100 ng/ml IL-15 with or without 1 mM 2-deoxy-ᴅ-glucose (2DG). (A) Representative flow histogram shows granzyme B 
(Gzmb) levels in naive (filled) and activated NK cells cultured without (black) or with (green) 1 mM 2DG. Summary data are normalized to mean fluorescence 
intensity (MFI) of naive NK cells (n = 9/group, 5 separate experiments, ratio paired t test performed on raw data). (B) NK cells were incubated at a 1:1 ratio 
with Ba/F3-m157 target cells for various times; conjugates were detected by flow cytometry. Representative flow cytometry shows CFSE+ and CellTrace 
Violet (CTV)+ conjugates, and conjugation curve shows percentage of CFSE+ cells conjugated (n = 2–3 technical replicates, representative of 3 separate 
experiments, 2-way ANOVA). (C–F) NK cells were incubated with Ba/F3-m157 cells for 40 minutes at a 2:1 ratio. (C and D) Fluorescence microscopy of NK:Ba/
F3-m157 conjugates show convergence of granules (green, Gzmb), Ly49H accumulation at the synapse (yellow), polarization of the microtubule organizing 
center (MTOC, blue) toward the synapse, and actin accumulation (red). Scale bar: 2 μm. Representative images for the range of control and 2DG-treated 
NK cells are shown. (E) Quantification of actin accumulation by area × intensity of synapse – (NK + target) (n = 25–27 conjugates/group, 4 experiments, 
distribution analyzed by Kolmogorov-Smirnov test). (F) Quantification of MTOC-synapse distance in μm, not significant by 2-tailed Welch’s t test for means 
or Kolmogorov-Smirnov test (n = 58–60 conjugates/group, 5 experiments). For A and B, data show mean ± SEM. For E and F, the gray box displays median, 
25th, and 75th percentiles. *P < 0.05, ***P < 0.001.
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The defect in target clearance in 2DG-treated mice was not due to differences in NK cell numbers, as 
there were no significant differences in the number or percentage of  NK cells (Figure 3B), or in Ly49H 
expression on NK cells (not shown), in the spleens or livers at this early time point. To determine whether 
NK cells had a defect in cytotoxic capacity, intracellular Gzmb and degranulation, as measured by cell- 
surface expression of  CD107a, were tested. NK cells rapidly upregulate Gzmb and other cytotoxic proteins 
after infection with MCMV, and levels of  Gzmb at day 2 in NK cells from infected mice were significantly 
higher than in naive mice. However, there were no differences between 2DG- and PBS-treated mice in 
the percentage of  Gzmb+ NK cells or in the amount of  Gzmb protein as measured by mean fluorescence 
intensity (MFI) (Figure 3C). NK degranulation measured by cell-surface level of  CD107a stained directly 
ex vivo was equivalent between 2DG-treated and PBS control mice (Figure 3D). Similarly, no differences 
in T cell numbers, Gzmb expression, or degranulation were detected (Supplemental Figure 2, A–C). These 
results suggest that NK cells from 2DG-treated mice retained cytotoxic machinery but were unable to 
mount productive target cell killing.
Figure 3. 2DG treatment in vivo caus-
es decreased target clearance during 
MCMV infection. Female WT C57BL/6 
mice were infected with 1 × 105 PFU 
murine cytomegalovirus (MCMV), 
treated daily with 2-deoxy-ᴅ-glucose 
(2DG) or PBS, and analyzed on day 
2 after infection. (A) Equal numbers 
of labeled nontarget splenocytes 
and target m157-transgenic spleno-
cytes were injected i.v., and target 
clearance in the spleen was measured 
4 hours later (n = 7–12 individuals/
group, 2 separate experiments). (B) 
The number and percentage of NK 
cells isolated from the spleen or liver 
(n = 7–8/group, 2 experiments). (C) 
Flow plots and mean fluorescence 
intensity (Gzmb MFI) measured by 
flow cytometry in Ly49H+ (solid) and 
Ly49H- (hatched) NK cells from the 
spleen or liver (n = 4/group, represen-
tative of 2 experiments). (D) CD107a 
expression on splenocytes (n = 7–8/
group, 2 experiments). Data show 
mean ± SEM. All statistical analyses 
are 1-way ANOVA with Tukey’s multi-
ple comparison test. *P < 0.05, **P < 
0.01, ***P < 0.001.
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NK cells in 2DG-treated mice produce normal levels of  IFN-γ during MCMV infection. NK cell production 
of  IFN-γ peaks at 1.5 days after MCMV infection in response to systemic release of  inflammatory cyto-
kines, including IL-12 made by DCs (43). While others have observed that IFN-γ production by LAK 
cells in vitro or by poly(I:C)-stimulated NK cells in vivo is susceptible to inhibition by 2DG (12), we pre-
viously demonstrated in vitro that naive NK cell production of  cytokine-driven IFN-γ is not inhibited 
by 2DG or by culture in glucose-free media (10). In agreement with our previous in vitro studies, there 
was no difference in IFN-γ production during MCMV infection with 2DG treatment (Supplemental 
Figure 4. 2DG treatment in vivo confers MCMV susceptibility. Female WT C57BL/6 mice were infected with 1 × 105 PFU murine cytomegalovirus (MCMV) 
and treated daily with 2-deoxy-ᴅ-glucose (2DG) or PBS. Viral copy number by quantitative PCR from the spleen and liver was measured on (A) day 2 or (B) 
day 4 after infection, shown as copies of MCMV ie1 gene/copies of β-actin × 1,000 (n = 3–8 individuals/group, 2 experiments, 1-way ANOVA on log-trans-
formed data). (C) Total numbers of lymphocytes and NK cells from the spleen or liver at day 4 after infection. (D) Representative flow cytometry and 
summary data showing the percentage of BrdU+Ly49H+ NK cells (open) and Ly49H– NK cells (hatched), assessed 3 hours after BrdU injection. For C and D, 
n = 7–8/group, 2 experiments, 1-way ANOVA with Tukey’s multiple comparison test. (E) Survival of uninfected mice compared with infected mice treated 
with 2DG or PBS (n = 20/group, 4 experiments, log-rank Mantel-Cox test). Data shown as mean ± SEM or survival. *P < 0.05, ***P < 0.001.
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Figure 3). These data also suggest an intact innate immune cytokine response to MCMV in the context 
of  systemic 2DG injection, since early NK cell IFN-γ production is dependent on cytokines produced 
by antigen-presenting cells.
2DG treatment causes susceptibility to MCMV infection. To test whether impaired NK cell clearance of  
targets correlates with susceptibility to infection, MCMV copy number was assessed in the spleen and 
liver. 2DG treatment was associated with higher viral burdens as early as day 2 after infection in the spleen 
(Figure 4A), and by day 4, there was significant loss of  viral control, evidenced by high viral copy num-
ber in both the spleen and liver (Figure 4B). Data on organ-specific control of  MCMV is mixed, but one 
hypothesis is that NK cell IFN-γ is more important for control of  MCMV in the liver, while NK cell cyto-
toxicity and Ly49H are responsible for control of  infection in the spleen (44–47), which is consistent with 
our findings.
By day 4 after infection, 2DG treatment and high viral burden led to a decrease in the total number 
of  splenocytes and liver lymphocytes (Figure 4C), with correspondingly decreased numbers of  NK cells. 
There were no differences in the numbers of  lymphocytes or NK cells with 2DG treatment alone, and cell 
loss was specifically associated with uncontrolled MCMV infection in 2DG-treated mice. Low NK cell 
numbers at this time point were not due to decreased NK cell proliferation, since the percentage of  NK 
cells with BrdU incorporation at day 4 after infection was similar with and without 2DG treatment (Figure 
4D). T cell numbers and BrdU incorporation were also similar with 2DG treatment (Supplemental Figure 
2, D and E). Thus, 2DG did not affect in vivo receptor–mediated proliferation of  Ly49H+ NK cells, but it 
did inhibit in vitro IL-15–stimulated proliferation.
Loss of  viral control with 2DG treatment was associated with significant mortality, with 80% of  nor-
mally resistant female B6 mice dying between days 5 and 6 after infection (Figure 4E). 2DG treatment 
alone without infection had no effect on survival. Mortality was dependent on both the dosage of  virus 
and drug, as lower doses of  MCMV or 2DG did not lead to mortality (Supplemental Figure 4). Together, 
these data show that glucose metabolism was crucial in the clearance of  an NK-dependent viral infection.
IL-15 can rescue MCMV-infected, 2DG-treated mice. In vitro, culture with IL-15 enhances NK cell metabo-
lism, preferentially glycolysis, and confers some resistance to the effects of  metabolic inhibition; specifical-
ly, IFN-γ production in glucose-free media was partially restored if  NK cells were primed with IL-15 (10). 
Since NK cell cytotoxicity was susceptible to glycolytic inhibition, we tested whether IL-15 could mitigate 
NK cell dependence on glucose during MCMV infection. Mice were treated with the human IL-15 super-
agonist complex ALT-803, which is composed of  IL-15 with the N72D mutation and IL-15Rα fused to the 
Fc of  IgG1. ALT-803 has been shown to activate NK cells and CD8+ T cells, and it exhibited antitumor 
and antiretroviral activities in various experimental animal models (48–57). Mice were treated with 5 μg of  
ALT-803 at 3 and 1 days prior to infection, which increases the number and percentage of  NK cells in the 
spleen by 2- to 10-fold on the day of  infection (data not shown). ALT-803 treatment significantly increased 
the baseline and maximal glycolytic and oxidative capacity of  NK cells, but it did not alter the ratio of  oxi-
dative phosphorylation to glycolysis (OCR/ECAR), suggesting that ALT-803–activated NK cells had high 
metabolic potential and activity but did not especially favor glycolysis (Figure 5A). This is in contrast to 
IL-15 treatment in vitro, which we previously demonstrated decreased the OCR/ECAR ratio (10).
Treatment with ALT-803 rescued the deficit in NK cell target clearance at day 2 after infection in 
MCMV-infected, 2DG-treated mice (Figure 5B). ALT-803 treatment increased the total number of  splenic 
NK cells and Gzmb expression, but neither of  these was affected by 2DG (Figure 5, C and D). There was no 
difference in splenic MCMV copy number at day 2 after infection between 2DG-treated and PBS control mice 
that had been pretreated with ALT-803 (Figure 5E), suggesting enhanced viral control as compared with 2DG 
treatment alone (Figure 4A). However, liver MCMV copy number was increased with 2DG and ALT-803 
treatment as compared with ALT-803 alone (Figure 5E). The difference in liver MCMV burden appears to 
be due to decreased MCMV copy numbers in the liver of  ALT-803–treated mice, when compared with those 
with MCMV infection alone (Figure 4A), and due to the loss of  this protective effect with 2DG treatment”. 
To assess survival, mice were monitored and received an additional dose of  ALT-803 at day 2 after infection. 
Mice receiving ALT-803 were completely protected from MCMV infection with 2DG treatment (Figure 5F). 
Thus, treatment with ALT-803 rescued both the target clearance and survival deficits induced by 2DG.
IL-15 rescue is dependent on NK cells. To determine whether enhanced target clearance and survival with 
ALT-803 were NK-dependent, NK cells or CD8+ T cells — the 2 major cell types responsive to IL-15 
— were antibody depleted (α-NK1.1 or α-CD8b). Mice depleted of  NK or CD8+ cells, or control-treated 
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animals, received ALT-803 prior to MCMV infection with 2DG treatment (Figure 6A and Supplemen-
tal Figure 5A). NK depletion completely abrogated m157-transgenic target cell clearance and significantly 
increased MCMV copy number at day 2 after infection (Figure 6, B and C). Target cell clearance and 
MCMV copy number were not affected by CD8 depletion (Supplemental Figure 5, B and C), suggesting 
that bystander activation of  CD8+ memory T cells by ALT-803 did not affect control of  acute MCMV 
infection in naive mice. NK-depleted mice had significantly increased mortality (Figure 6D), while CD8+ T 
cell depletion had no effect on survival (Supplemental Figure 5D), demonstrating that the survival of  ALT-
803–treated mice is dependent on NK cells. NK depletion did not result in the 80%–100% lethality of  2DG 
treatment alone, indicating that ALT-803 may have some antiviral effects on NK1.1– cells (e.g., intraepithe-
lial lymphocytes in the gut that can respond to IL-15, or DCs that produce and display IL-15; ref. 58). It is 
Figure 5. NK activation with ALT-803 rescues MCMV susceptibility caused by 2DG treatment. (A) Female WT C57BL/6 mice were treated with 5 μg 
ALT-803 twice, NK cells were purified from their spleens, and a glycolytic stress test was performed. Representative graph showing baseline, normal 
(+glucose), and maximal (+oligomycin) extracellular acidification rate (ECAR) in control vs. ALT-803–treated mice. Average ECAR, oxygen consumption rate 
(OCR), and OCR/ECAR ratio are shown after glucose addition (n = 3 individuals/group, 2 separate experiments, 2-tailed t test). (B–E) ALT-803–treated mice 
were infected with 1 × 105 PFU murine cytomegalovirus (MCMV) and treated with 2-deoxy-ᴅ-glucose (2DG) daily. (B) Clearance of m157-transgenic targets 
from the spleens of infected and uninfected mice ± ALT-803 and 2DG on day 2 after infection (n = 5/group, representative of 2 experiments, 1-way ANOVA). 
(C) The number and percentage of NK cells isolated from the spleens or livers of mice in B. (D) Mean fluorescence intensity of granzyme B (Gzmb MFI) in all 
NK cells from B. (E) Viral copy number measured by quantitative PCR from the spleens and livers collected in B, shown as copies of MCMV ie1 gene/copies 
of β-actin × 1,000. For C–E, n = 10/group, 2 experiments, 1-way ANOVA, using log-transformed data for E. (F) Mice were given an additional dose of ALT-803 
2 days after infection and followed for 10 days. Survival of mice with no treatment (gray dashed line), 2DG treatment (black), ALT-803 treatment (blue), 
or ALT-803 with 2DG (green) (n = 10/group, 2 experiments, log-rank Mantel-Cox test). Data shown as mean ± SEM or survival. **P < 0.01, ***P < 0.001. 
Asterisks in A, B, and F indicate treatment with ALT-803.
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also possible that NK cells remained or developed after antibody depletion treatment due to IL-15’s strong 
survival and differentiation signaling; while there were no detectable NK cells in the blood or spleens of  the 
majority of  mice (data not shown), the efficacy of  depletion in other organs was not evaluated.
mTOR inhibition leads to a similar survival defect with MCMV infection, which is rescued with IL-15 prim-
ing. High-dose IL-15 signaling induces mTOR signaling, and mTOR activity is linked to the upregula-
tion of  glycolysis (11, 59, 60). We tested whether inhibition of  mTORC1 led to susceptibility to MCMV 
infection, similar to 2DG treatment. Based on our finding that glycolytic inhibition impaired NK cell 
responses and led to mortality with MCMV, we hypothesized that mTOR signaling is required for NK 
cell–protective effects during MCMV, as was suggested by a prior study demonstrating increased viral 
copy number in rapamycin-treated MCMV-infected mice (59). Indeed, daily injection with 1.5 mg/kg 
rapamycin, an inhibitor of  mTOR complex 1 (mTORC1), during MCMV infection led to susceptibil-
ity similar to 2DG treatment, with death 5–6 days after infection (Figure 6E). Also similar to 2DG, 
IL-15 priming with ALT-803 was protective and completely abrogated the effects of  rapamycin during 
MCMV infection (Figure 6F). This suggests that, while IL-15 signaling has been described to upreg-
ulate mTOR and glycolysis, continued signaling through mTOR or maintenance of  glycolysis is not 
required after IL-15 priming to sustain NK cell effector function.
Human NK cell cytotoxicity is reduced by treatment with 2DG. Relatively little is known about the 
effects of  metabolism on human NK cell function, particularly cytotoxicity. To investigate whether 
human NK cells have a glycolytic requirement for cytotoxicity similar to the murine system, human 
NK cells were activated for 24 hours with IL-15 in the presence of  varying doses of  2DG, then used 
in killing assays with K562 targets. Human NK cells were more resistant to 2DG than murine NK 
cells, but killing of  K562 target cells was significantly decreased when cells were primed with IL-15 
in the presence of  20–40 mM 2DG (Figure 7A). Actin accumulation and MTOC polarization were 
measured, and there were no significant defects in either (Figure 7, B and C). Thus, both human and 
Figure 6. ALT-803 rescue of 2DG-treated mice 
requires NK cells, and ALT-803 priming can 
eliminate susceptibility to MCMV caused 
by mTOR inhibition. (A) Mice were either 
depleted of NK cells using α-NK1.1 or treated 
with IgG2a; they were given 2 doses of ALT-
803 and infected with 1 × 105 PFU murine 
cytomegalovirus (MCMV). 2-Deoxy-ᴅ-glucose 
(2DG) was given every 24 hours, and mice 
were euthanized on day 2 for assessment of 
(B) clearance of m157-transgenic targets from 
the spleen and (C) viral copy number from 
the spleen and liver; they were measured by 
quantitative PCR and log-transformed (n = 10 
individuals/group, 2 separate experiments, 
2-tailed t test). (D) To assess susceptibility, 
an additional NK depletion was given at day 
3 (red, n = 30); control mice were treated with 
IgG2a (black, n = 23). Mice were followed for 10 
days (3 separate experiments). (E) Mice were 
infected with MCMV, given daily i.p. injections 
of 1.5 mg/kg rapamycin (green) or vehicle 
(black), and monitored for susceptibility (n = 
10/group, 1 experiment). (F) ALT-803 was given 
to MCMV-infected, rapamycin-treated mice on 
the same schedule as for 2DG-treated mice, 
with doses at –3, –1, and +2 days relative to 
infection (n = 10/group, 1 experiment). Data 
show mean ± SEM or survival in D–F analyzed 
by log-rank Mantel-Cox test. ***P < 0.001. 
Asterisks in A and D indicate treatment with 
ALT-803.
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murine NK cell killing can be dampened by inhibition of  
glucose metabolism, though it is unclear if  there are similar 
mechanisms regulating this effect.
Treatment of  CMV reactivation in a patient with an IL-15 super-
agonist. Our results demonstrating that IL-15 treatment leads 
to enhanced protection against MCMV suggest that this cyto-
kine may have therapeutic potential in patients. A 23-year-old 
CMV-seropositive male with dyskeratosis congenita and aplas-
tic anemia received a matched sibling allogeneic HCT from his 
CMV-seronegative brother with full engraftment by 9 months 
(see Methods for case presentation). This patient experienced 
5 episodes of  CMV reactivation after transplant, which mani-
fested as viremia without organ disease (Figure 8A). Three epi-
sodes of  CMV viremia within the 9 months after HCT improved 
with antiviral therapy. A fourth episode at 18 months after HCT 
resolved with CMVpp65-specific T cell adoptive transfer.
At 51 months after HCT, the patient again experienced 
CMV reactivation. Because of  recurrent CMV viremia, this 
patient was treated with compassionate-use ALT-803. Abso-
lute numbers of  peripheral blood NK cells were within nor-
mal limits at the time of  ALT-803 administration. The patient 
received 4 weekly doses followed by 2 biweekly doses of  ALT-
803 at 6 μg/kg per dose. No other antiviral therapy was given 
before or during the time of  ALT-803 administration. With-
in 2 months, CMV viremia was below the limit of  detection 
(Figure 8B), and CMV levels remained low for 7 weeks after 
ALT-803 therapy without additional antiviral therapy. Unfor-
tunately, this patient experienced a recurrence of  viremia 
when immunosuppressive therapy was required for treatment 
of  posttransplant lymphoproliferative disorder.
NK cell function in this patient before treatment and 7 or 14 days after each dose of  ALT-803 was 
evaluated. The patient had an elevated proportion of  CD57+NKG2C+ NK cells before treatment (~50%), 
consistent with the presence of  CMV-adapted NK cells typically seen after CMV infection. This population 
of  CMV-adapted NK cells was not altered by treatment with ALT-803 (data not shown). NK cell IFN-γ 
production after overnight stimulation of  cryopreserved peripheral blood mononuclear cells (PBMC) with 
IL-12 + IL-18 increased following ALT-803 treatment (Figure 8C). Although the absolute IFN-γ response 
was lower in the patient’s cells than in PBMC from healthy controls treated with IL-12 + IL-18 (mean 
± SD: 44.69% ± 2.96% IFN-γ–producing NK cells, n = 8 controls), the increased responsiveness in this 
patient suggests that NK cell function was augmented by ALT-803 therapy.
Discussion
Here, we examine the role of  glycolysis in NK cell functions in vitro and in vivo. We found that the glucose 
metabolism inhibitor 2DG prevented IL-15–induced NK cell proliferation and priming of  cytotoxicity in 
vitro. Using MCMV as an NK-dependent infection model, we demonstrate that administration of  2DG 
in vivo impaired NK-mediated target clearance and significantly increased susceptibility of  mice to infec-
tion. These defects could be rescued in an NK-dependent manner with the IL-15 superagonist ALT-803. 
Treatment with an mTORC1 inhibitor led to a similar susceptibility to infection, which was also rescued 
by ALT-803 priming, suggested that IL-15–primed NK cells have mTOR- and glycolysis-independent sus-
tained effector function. In a patient, treatment with ALT-803 also boosted NK cell function and was 
associated with clearance of  CMV viremia, suggesting that targeting NK cell function in humans can lead 
to enhanced CMV control.
Our in vitro findings show that culture in 2DG blocks the ability of  IL-15 to activate NK cell functions 
including proliferation, Gzmb production, and acquisition of  enhanced cytotoxic functions. Cytotoxic 
defects were target cell–line specific, suggesting that certain pathways of  NK cell activation may be able to 
Figure 7. 2DG decreases human NK cell cytotoxicity. Human NK cells were isolated 
from healthy donors, enriched using RosetteSep, and cryopreserved. Cells were 
later thawed and activated in 100 ng/ml human IL-15 for 24 hours in various 
concentrations of 2DG. (A) NK cells were washed and cocultured with K562 targets 
for 4 hours at various E:T ratios; representative killing assay shown (n = technical 
duplicate, representative of 6 donors across 4 experiments, mean with replicates 
shown). (B and C) NK cells from control conditions and 20–40 mM 2DG were 
cultured at a 2:1 ratio with K562 cells and imaged after 40 minutes. (B) Quantifica-
tion of actin accumulation by area × intensity of synapse – (NK + target) (n = 41–43 
conjugates/group, 1 experiment). (C) Quantification of distance from the micro-
tubule organizing center (MTOC) to synapse in μm (n = 67–61 conjugates/group, 2 
experiments). Gray boxes show median, 25th, and 75th percentiles. Neither B nor C 
was significant by 2-tailed t test or Kolmogorov-Smirnov test.
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overcome the dampened activation state of  2DG-treat-
ed NK cells or that certain pathways require glycolyt-
ic metabolites for signaling. Possible mechanisms for 
2DG’s effects on cytotoxicity include downregulation 
of  Gzmb — leading to less cytotoxic granules — and 
altered actin accumulation at the IS. Actin accumulation 
is crucial for NK cell cytotoxicity, as evidenced by diseas-
es associated with defects in actin accumulation such as 
Wiskott-Aldrich Syndrome, where NK cells fail to form 
conjugates or kill target cells (61). Although conjugation 
to target cells and MTOC polarization toward the syn-
apse appeared normal in 2DG-treated NK cells, altered 
actin accumulation could be indicative of  a less stable 
conjugation that could lead to slower or less effective 
killing, or could interfere with release of  target cells and 
thus interfere with serial killing by NK cells. Interesting-
ly, Wiskott-Aldrich NK cell defects can be reversed by 
IL-2 administration, as IL-2 activates an alternate actin 
polymerizing pathway (62, 63). Since IL-15 and IL-2 are 
closely related, this may provide a potential mechanism 
for IL-15 rescue of  2DG-induced deficits.
The observed target clearance defect caused by 
2DG treatment resulted in higher viral replication, over-
whelming infection, and mortality. MCMV infection has 
a steep LD50 curve (41), and loss of  control of  infection 
in 2DG-treated mice phenocopies mortality observed 
in mice depleted of  Ly49H+ NK cells or total NK cells 
(24). Notably, not all NK cell functions were affected by 
2DG, with intact IFN-γ production in vitro (10) and in 
vivo, and proliferation in vivo. Normal proliferation was somewhat surprising, as proliferating lympho-
cytes have been well described to rely on aerobic glycolysis (64, 65). This may be due to non–IL-15 sig-
nals in MCMV-infected mice, such as the presence of  additional cytokines or activating receptor ligands, 
that could allow NK cells to proliferate despite glycolytic inhibition. The underlying mechanism for this 
glycolytic requirement for NK cell cytotoxicity can be partially explained by some of  the findings here. 
2DG decreases Gzmb upregulation in response to IL-2 + IL-12 (12) or IL-15 stimulation in vitro and after 
poly(I:C) injection in vivo (12). While 2DG did not appear to inhibit Gzmb upregulation in response to 
MCMV infection, this could be explained by different kinetics of  Gzmb accumulation in response to differ-
ent in vivo stimuli or by accumulation of  Gzmb in 2DG-treated NK cells that are not actively degranulating 
and killing target cells. It is possible that killing defects in vivo are caused by changes in actin dynamics 
rather than Gzmb. Although actin accumulation defects did not alter conjugation in vitro, this may be due 
to the ready abundance and proximity of  target cells. In vivo actin dynamics are crucial in NK cell traffick-
ing, and minor defects in the ability to polymerize actin could lead to decreased numbers of  NK cells at 
sites of  infection.
Although 2DG administration is confounded by systemic effects, prior model systems have demon-
strated that 2DG does not lead to generalized susceptibility to infection, as 2DG treatment did not increase 
susceptibility to listeria infection (66) and decreased virulence of  other viruses, including HSV (67–69). 
Combined with our evidence that Ly49H-specific target clearance is decreased with 2DG and that deficient 
target clearance and survival can be rescued through IL-15, there is clear evidence of  NK-specific defects 
with 2DG. However, NK cell–specific genetic KO of  metabolic enzymes are necessary to further interro-
gate the role of  metabolism in NK cell functions in vivo.
While NK cells require glycolysis during viral infection for optimal killing, pretreatment with IL-15 
releases NK cells from their reliance on glucose metabolism, similar to what we previously observed in 
vitro for IFN-γ (10). ALT-803 injection altered the metabolic rate of  NK cells, leading to increased gly-
colysis and oxidative phosphorylation, and preserved NK cell–mediated target clearance in the presence 
Figure 8. ALT-803 treatment of CMV reactivation in a posthematopoietic cell transplant 
patient. (A) The patient’s course of cytomegalovirus (CMV) reactivation after hema-
topoietic cell transplant (HCT), with periods of viremia detectable by quantitative PCR 
assay shown as orange bars. Posttransplant immunosuppression is shown as a blue bar. 
Years 1–4 after HCT marked. (B) During reactivation event 5, CMV levels responded to 
treatment with ALT-803, as indicated by arrows. Points below limit of detection (dashed 
line) at 137 copies/ml are rounded up. (C) To assess IFN-γ production by the patient NK 
cells, peripheral blood mononuclear cells (PBMC) were collected and cryopreserved before 
ALT-803 treatment or 7–14 days after the listed ALT-803 dose. PBMC were thawed and 
stimulated with 10 ng/ml IL-12 and 100 ng/ml IL-18 for 16 hours; they were then washed 
and plated for an additional 5 hours (n = 4 technical replicates, 1 experiment, shown as 
mean ± SEM, statistical significance in a 1-way ANOVA compared with the quantity of 
cells before dose 1 shown above relevant column). *P < 0.05, ***P < 0.001.
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of  2DG. Mice pretreated with ALT-803 were protected from MCMV infection when treated with either a 
glycolytic inhibitor or an inhibitor of  mTORC1, suggesting that these pathways are not critical for IL-15–
primed NK cell antiviral responses.
The underlying mechanism for IL-15 reversing NK cell dependence on glucose metabolism and mTOR 
activation is unknown. IL-15 is well described to promote NK cell differentiation, expansion, Gzmb expres-
sion, cytokine production, and cytotoxicity (32, 70). We have previously shown that IL-15 upregulates NK 
cell metabolic capacity in vitro, especially glycolysis (10; here, we demonstrate that ALT-803 significantly 
increases metabolism in vivo, suggesting that IL-15 fundamentally alters cellular metabolic requirements. 
This altered metabolic state could lead to more flexible fuel usage by NK cells, allowing alternate fuels such 
as fatty acids, glutamine, or pyruvate to fuel NK cell function if  glucose metabolism is limited. Alternately, 
we now have evidence that both cytokine-activated IFN-γ production (10) and clearance of  target cells 
during MCMV infection become less metabolically dependent with IL-15 pretreatment, suggesting that 
IL-15 increases the range of  stimuli and functions that are metabolically independent. Recent studies have 
demonstrated a role for mTORC1 in IL-15 priming and NK cell responses to MCMV. mTORC1 activates 
glycolysis through HIF-1 and c-myc signaling, in addition to orchestrating broader cell growth programs 
(71). High-dose IL-15 signaling has been shown to be dependent on mTORC1 (11, 59), which likely con-
tributes to IL-15–induced upregulation of  glycolysis. However, here we demonstrate for the first time to 
our knowledge that, after IL-15 priming, mTORC1 signaling is not required for in vivo NK cell function, 
as shown by complete protection against an NK-dependent infection, MCMV, in rapamycin-treated mice 
pretreated with ALT-803. These findings distinguish the effects of  mTORC1 signaling on priming versus 
maintenance of  NK cell effector function.
The concept of  augmenting the antiviral effects of  NK cells with IL-15 agonists may be particularly 
relevant in patients after HCT and/or patients receiving immunosuppression targeting T cell responses. Fol-
lowing HCT, NK cells are the first lymphocyte population to emerge from the new BM and, thus, represent 
an important population to target for antileukemic and infection responses (72). In some cases, NK cells are 
reconstituted after HCT but are less functional for months, with reduced capacity for IFN-γ production and 
cytotoxicity (73, 74). Here, we show that treatment with an IL-15 superagonist significantly boosted NK cell 
antiviral responses in mice and, in 1 patient, was associated with clearance of  CMV infection in the absence 
of  other antiviral therapy. Although limited conclusions can be drawn from a single patient, these studies 
suggest that clinical investigation of  IL-15 agonists for treatment of  refractory viral infections, particularly 
CMV, is warranted. Here, we demonstrate that IL-15 activation of  NK cells decreases NK cell reliance on 
glucose metabolism and mTOR signaling in vivo and may be a strategy to enhance NK cell function in 
metabolically challenging environments such as inflammatory and tumor microenvironments in patients.
In summary, our findings suggest that limiting glucose metabolism impairs NK cell killing and host 
antiviral responses to CMV, which can be rescued with IL-15–based priming. Such therapies may be par-
ticularly beneficial for patients after HCT, who may have normal numbers of  NK cells but poor NK cell 
function. Additional investigations of  the mechanisms by which metabolism alters NK function will be 
important for targeting these innate immune lymphocytes for immunotherapy and may provide insight into 
the metabolic regulation of  killing in other cytotoxic lymphocytes.
Methods
Mice and MCMV infection. All mice were maintained in specific pathogen-free conditions, used between 
6 and 12 weeks of  age, and euthanized in accordance with institutional guidelines. C57BL/6 mice were 
purchased from Charles River Laboratories or from The Jackson Laboratory, and m157-transgenic mice 
on the C57BL/6 background (42) were bred in-house. Seven- to 11-week-old C57BL/6 female mice were 
injected i.p. with 1 × 105 PFU of  Smith strain salivary gland MCMV (ATCC, prepared in BALB/c mice) 
or media as a control. 2DG (19 mg; MilliporeSigma) was given i.p. after infection and every 24 hours 
(~1 g/kg per mouse) or PBS as a control. For proliferation assays, mice were injected with 2 mg BrdU 
(BD Biosciences) i.p. 3 hours before harvest. For IL-15 superagonist treatment, 5 μg ALT-803 (Altor Bio-
Science) was injected i.p. 3 days and 1 day before MCMV infection and 2 days after infection. For NK 
and CD8 depletion, 100 μg of  α-NK1.1 (PK136, BioXcell), 250 μg α-CD8b (53-5.8, BioXcell), or 100 μg 
murine IgG2a (C1.18.4, BioXcell) was administered i.p. 6 days before MCMV infection, the day of  infec-
tion, and 3 days after infection. Mice were bled 24 hours before infection, or spleens were examined at the 
time of  euthanasia to confirm NK or CD8+ T cell depletion by loss of  CD3–NKp46+DX5+ or CD3+CD8a+ 
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cells (data not shown). Rapamycin (Selleck Chemicals) was solubilized in 4% EtOH (MilliporeSigma), 
5% Tween 80 (MilliporeSigma), 5% PEG400 (MilliporeSigma), and water, and 30 μg (~1.5 mg/kg) or an 
equivalent amount of  vehicle was injected i.p. daily during MCMV infection.
In vitro assays. Primary splenocytes from female C57BL/6 mice were cultured in RPMI 1640 (Mediatech) 
supplemented with 10% FBS (MilliporeSigma), L-glutamine to a final concentration of  4 mM (MilliporeSig-
ma), 50 μM 2-ME (MilliporeSigma), and antibiotics (penicillin/streptomycin). NK cells were enriched from 
spleens using negative-selection magnetic bead kits (Miltenyi Biotec and StemCell Technologies). Purity 
ranged from 55%–90% at time of  plating, and 77%–99% after 72 hours of  activation. For IL-15 activation, 
purified NK cells were cultured in 100 ng/ml IL-15 (PeproTech) for 72 hours with or without 1 mM 2DG. 
For proliferation assays, purified NK cells were stained with 1 μM CFSE (Invitrogen) before culture.
For mouse NK cell killing assays, NK cells were washed and plated in V-bottom plates at estimated 
10:1, 5:1, and 1:1 NK/target ratios with 1 × 104 CellTrace Violet–labeled target cells, including RMA-S 
(from W. Yokoyama, Washington University), Ba/F3-m157 (from W. Yokoyama; ref. 29), and YAC-1 
(ATCC). Cell lines tested negative for mycoplasma. Effector/target ratios were calculated based on NK cell 
purity by flow cytometry. After 4 hours, cells were stained with 7-AAD (Calbiochem) for 15–30 minutes 
before flow cytometry, and specific lysis was calculated by subtracting the percentage of  7-AAD+ target 
cells from wells without effectors. For mouse NK cell conjugation assays, NK cells were labeled with CFSE 
and Ba/F3-m157 target cells with CellTrace Violet (CTV, Invitrogen). Cells were spun down at a 1:1 NK/
target ratio, incubated in 37°C for 15, 30, or 120 minutes, and then vortexed gently and fixed in 1% parafor-
maldehyde. Percent conjugated NK cells was calculated by calculating the percentage of  CFSE+CTV+ cells 
compared with all CFSE+ cells.
Human NK cells from healthy donors were enriched using RosetteSep (StemCell). For killing assays, 
previously cryopreserved NK cells were plated in 100 ng/ml IL-15 (Miltenyi Biotec) and varying con-
centrations of  2DG for 22–26 hours, followed by incubation with labeled K562 targets for 4 hours at the 
indicated E:T ratios. Cells were then stained with 7-AAD, and specific lysis was calculated. For conjugation 
assays, NK cells were incubated with IL-15 and 2DG for 22–26 hours and then cocultured with K562 tar-
gets at a 2:1 ratio for 40–50 minutes. To assess patient NK cell function, cryopreserved PBMC from serial 
time points were thawed, incubated for 16 hours with human IL-12 (10 ng/ml) and IL-18 (100 ng/ml), 
washed, plated in replicates of  4 per sample, and incubated for an additional 5 hours prior to intracellular 
staining for IFN-γ protein.
Flow cytometry. Cell viability was measured by live/dead stain (Zombie Yellow, BioLegend), followed 
by blocking with anti-FcγRIII (2.4G2, from W. Yokoyama) prior to surface staining. Cells were fixed with 
1% paraformaldehyde for surface analysis, or fixed with Cytofix/Cytoperm (BD Bioscience) for intracellu-
lar staining. For intranuclear staining, cells were fixed in Cytofix/Cytoperm and Cytoperm Plus buffer (BD 
Biosciences) and DNAse treated. Data was acquired on a Cytek-modified FACScan (BD Biosciences and 
Cytek) or LSRFortessa (BD Biosciences); data was analyzed using FlowJo 7.6.5. Geometric MFI, and per-
cent proliferated were calculated by FlowJo. The following fluorochrome-conjugated antibodies were used: 
CD3ε (145-2C11, BD Biosciences, BioLegend), CD4 (GK1.5, Leinco), CD8α (53-6.7, BD Biosciences), 
CD11b (M1/70, BD Biosciences), CD11c (HL3, BD Biosciences), CD19 (eBio1D3, eBiosciences), IFN-γ 
(XMG1.2, BioLegend), Ly49H (3D10, BioLegend), NK1.1 (PK136, BD Biosciences), NKp46 (29A1.4, 
BD Biosciences), Gzmb (GB12, Invitrogen), and BrdU (559319, BrdU kit, BD Biosciences). CD107a was 
stained by incubating splenocytes with α-CD107a (1D4B, BD Biosciences) and GolgiStop (monensin, BD 
Biosciences) for 4 hours at 37˚C.
Confocal microscopy. Purified NK cells and Ba/F3-m157 or K562 targets were cocultured at a 2:1 ratio, 
incubated for 20 minutes at 37°C, applied to poly-L-lysine–coated coverslips, and incubated for an addi-
tional 20 minutes. Slides were fixed in Cytofix/Cytoperm (BD Biosciences) + 0.1% Triton X-100 (Mil-
liporeSigma) and then stained with the following antibodies: Ly49H (3D10, BioLegend), biotin-tubulin 
(236-10501, ThermoFisher), perforin (dG9, BioLegend), Gzmb (GB11, BioLegend), phalloidin (A12380, 
ThermoFisher), and streptavidin secondary antibody (S11222, ThermoFisher). Images were acquired on 
a Leica SP8 laser scanning confocal microscope equipped with a 100× 1.45 NA objective. Excitation was 
performed by tunable white light laser, and emission was detected by HyD detector (Leica Biosystems). 
Data were acquired using Leica LASAF and analyzed in Volocity 6.1.1 (Perkin Elmer) and 6.3 (Quorum 
Technologies). Measurement of  MTOC-synapse distance was single-blinded. Actin accumulation mea-
surements were unblinded and consisted of  the total area × average intensity of  three 1-μm squares spaced 
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evenly or where there was sufficient actin staining. Actin accumulation was calculated by area × intensity 
of  synapse – (NK + target) (75).
Extracellular flux. Extracellular flux assays were performed using a XF96 Analyzer (Seahorse Biosci-
ence). Purified splenic NK cells were cultured for 72 hours in 100 ng/ml IL-15 with or without 1 mM 2DG, 
or NK cells were purified from ALT-803– or control-treated mice. Cells were then washed and plated in at 
least duplicate for extracellular flux analysis of  OCR and ECAR as previously described (10, 76). Glycol-
ysis stress tests were performed in glucose-free DMEM (MilliporeSigma) supplemented with L-glutamine, 
sodium pyruvate, and 5% dialyzed FBS. Drug concentrations during the assay were as follows: glucose, 10 
mM; oligomycin, 100 nM; 2DG, 100 mM.
MCMV quantitative PCR. Tissue pieces (5 mm3) were minced and placed in Gentra Puregene Cell Lysis 
Buffer (Qiagen), and DNA was extracted following the manufacturer’s recommended protocol and dilut-
ed to 20–50ng/ml. MCMV immediate-early gene 1–specific (ie1-specific) primers and probe were used 
to determine viral copy number as described (47) and normalized to β-actin (Actb). Reactions were run 
in duplicate on a 7500 Fast Real-Time PCR instrument (Applied Biosystems) with an absolute standard 
curve. The limit of  reliable detection using the standard was 100 copies of  MCMV, and all values below 100 
were rounded up. Graphs represent ([copies MCMV ie1]/[copies Actb]) × 1,000. Statistics were performed 
on log-transformed data.
In vivo target clearance assay. Splenocytes were harvested from C57BL/6 mice and C57BL/6 m157-trans-
genic mice, stained with 10 μM or 1 μM CFSE, and mixed in a ~1:1 ratio. Cells (7 × 106 to 20 × 106) were 
injected by tail vein into mice that had been infected with MCMV 2 days prior and treated daily with 2DG 
or PBS. Mice were treated with 2DG, but not ALT-803, prior to the clearance assay. The remaining labeled 
cells in the spleen were analyzed 4 hours after transfer. Percent target clearance was calculated by compar-
ing the ratio of  m157-transgenic splenocytes (m157tg, targets) to WT splenocytes (nontargets) recovered to 
that originally injected: 1 – (%m157tg/%WT cells at 4 hr)/(%m157tg/%WT cells input) × 100.
Patient case presentation. A 23-year-old CMV-seropositive male with dyskeratosis congenita and severe 
aplastic anemia received a matched sibling allogeneic HCT from his CMV-seronegative brother. Condition-
ing was reduced intensity (fludarabine 40 mg/m2/day × 4, cyclophosphamide 50 mg/kg × 1, total body 
irradiation 2 Gy, and alemtuzumab 0.2 mg/kg/d × 5). Graft source was peripheral blood (9.3 × 106 CD34+ 
cells/kg), and the donor was his healthy brother (CMV seronegative). Graft-versus-host disease (GVHD) 
prophylaxis was with cyclosporine and mycophenolate mofetil, and viral prophylaxis was with high-dose 
acyclovir (800 mg 5 times daily) for approximately 25 days. Engraftment was complete as documented on 
day 28, and immunosuppressive medications for GVHD prophylaxis were discontinued 9 months after 
transplant. The patient developed no acute or chronic GVHD, relapse, or any major bacterial or fungal 
infection. However, the course of  transplant was complicated by recurrent CMV reactivation without organ 
disease. Within the first 100 days after HCT, he had 1 CMV reactivation episode treated successfully with 
valganciclovir (Hoffman-La Roche), and the viremia resolved after 21 days. The second episode occurred 4 
months after HCT and resolved after 3 months of  treatment with valganciclovir followed by foscarnet. The 
third episode occurred 9 months after HCT and resolved after 6 months of  treatment using maribavir (Clin-
icalTrials.gov, NCT01611974) followed by valganciclovir. The fourth episode occurred 18 months after 
HCT and resolved after 3 months with treatment using CMVpp65-specific T cell adoptive transfer (3 doses; 
ClinicalTrials.gov, NCT02136797; sponsored by Atara Biotherapeutics). This viral remission was durable 
and lasted for 31 months, at which time (51 months after HCT) the patient experienced another episode of  
reactivation. Mutation testing for antiviral resistance was negative.
Statistics. Statistics calculated in Prism 7 include mean, ± SEM, median, 25th/75th percentiles, 2-tailed 
student’s t test, Log-rank Mantel-Cox test, ordinary 1-way ANOVA, or 2-way ANOVA. All treatment 
groups used in an experiment were included in the ANOVA analysis, including controls; in nonsurvival 
experiments, mice that appeared uninfected were excluded from analysis. Tukey’s test and Sidak’s tests 
were used to correct for multiple comparisons, and adjusted P values are shown. The Kolmogorov-Smirnov 
test was calculated in Statistical Analysis System (SAS Institute) v9.4. P values represent 2-tailed probabil-
ity; α = 0.05. Data are presented with data averaged from each mouse or experiment as a separate point, 
and/or as mean ± SEM.
Study approval. All animal studies were performed at Washington University or Baylor College of  Med-
icine using an Animal Studies Committee (ASC) approved protocol, and they were conducted in accor-
dance with ASC regulations.
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For human studies, written informed consent was obtained from the patient presented here in agree-
ment with the guidelines of  the University of  Minnesota Human Research Protection Program. FDA 
approval for compassionate use of  ALT-803 was obtained (Investigational New Drug [IND] application 
no. 132197).
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